Short Interest in Lisata Therapeutics, Inc. (NASDAQ:LSTA) Drops By 56.6%

Lisata Therapeutics, Inc. (NASDAQ:LSTA) saw a significant drop in short interest in July. As of July 31st, there was short interest totaling 56,341 shares, a drop of 56.6% from the July 15th total of 129,920 shares. Based on an average daily volume of 155,428 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.7% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

LSTA has been the topic of a number of research reports. Weiss Ratings upgraded shares of Lisata Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday. HC Wainwright downgraded shares of Lisata Therapeutics from a “buy” rating to a “neutral” rating in a research report on Friday, May 15th. Finally, Zacks Research upgraded shares of Lisata Therapeutics to a “hold” rating in a research note on Monday, May 18th. Two equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lisata Therapeutics presently has an average rating of “Reduce” and a consensus price target of $15.00.

Institutional Trading of Lisata Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. acquired a new stake in Lisata Therapeutics during the 2nd quarter valued at $1,730,000. GSA Capital Partners LLP acquired a new position in Lisata Therapeutics in the 2nd quarter worth $321,000. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Lisata Therapeutics in the 2nd quarter valued at about $157,000. Renaissance Technologies LLC boosted its position in Lisata Therapeutics by 6.5% in the 1st quarter. Renaissance Technologies LLC now owns 131,715 shares of the company’s stock valued at $660,000 after buying an additional 8,000 shares during the last quarter. Finally, Deltec Asset Management LLC acquired a new stake in shares of Lisata Therapeutics during the first quarter valued at about $451,000. 8.94% of the stock is owned by hedge funds and other institutional investors.

Lisata Therapeutics Trading Down 3.5%

Shares of NASDAQ LSTA traded down $0.04 during trading on Friday, reaching $1.09. The company had a trading volume of 24,983 shares, compared to its average volume of 128,470. Lisata Therapeutics has a twelve month low of $0.99 and a twelve month high of $5.07. The stock has a 50-day moving average price of $2.64 and a two-hundred day moving average price of $3.63. The stock has a market capitalization of $9.82 million, a PE ratio of -0.59 and a beta of 0.88.

About Lisata Therapeutics

Lisata Therapeutics, Inc (NASDAQ: LSTA) is a clinical-stage biotechnology company focused on the discovery and development of novel therapies for severe diseases. The company’s pipeline comprises multiple product candidates in both preclinical and clinical stages, targeting autoimmune and inflammatory conditions through immunotherapeutic and cell-based approaches.

Lisata’s research and development activities are designed to improve upon existing treatment modalities by emphasizing targeted biologics and precision cell therapies.